Compare BHR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | NYXH |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 161.9M |
| IPO Year | N/A | 2021 |
| Metric | BHR | NYXH |
|---|---|---|
| Price | $2.29 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 662.9K | 180.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $1.26 |
| 52 Week High | $3.19 | $8.59 |
| Indicator | BHR | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 28.03 |
| Support Level | $2.19 | $1.26 |
| Resistance Level | $2.61 | $1.70 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 97.14 | 4.82 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.